Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL

NCT05679895 is registered in ClinicalTrials.gov with OneChain Immunotherapeutics as lead sponsor.

NCT NCT05679895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05679895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL
Lead sponsor
OneChain Immunotherapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
January 31, 2023
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic t-cell lymphoma, t-cell acute lymphoblastic leukemia